Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Klaus Fruh
Oregon Health & Science University, Department: None
Should you be removed from our database? Contact us at [email protected]. Read more below.
Vir Biotechnology, Inc.
Other : Exclusively licensed technology, through institution (OHSU considers this an SFI)
Please see attached pdf
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
NARRATIVE Developing a vaccine against malaria has been challenging and this parasitic disease remains one of the most frequent causes of death for small children worldwide. We propose a fundamentally new way of vaccinating against malaria that relies on the unique biology and immunology of a common virus: cytomegalovirus. Our research aims at stopping the malaria parasite at the liver stage, the site of greatest vulnerability, by using cytomegalovirus to elicit and maintain liver-stage specific cellular immune responses that will protect for life.
Filed on November 27, 2017.
Tell us what you know about Klaus Fruh's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Klaus Fruh filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Klaus Fruh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. (formerly called TomegaVax, Inc.) | $150,000 - $199,999 |
| Klaus Fruh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. | $150,000 - $199,999 |
| Klaus Fruh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. | $150,000 - $199,999 |
| Klaus Fruh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. | $0 - $4,999 |
| Klaus Fruh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.